Toxicity studies
are necessary for the development of a new drug.
Naphthalene is a bicyclic molecule and is easy to derivatize. In our
previous study, a derivative of naphthalene (4-phenyl,3,4-dihydrobenzoquinoline-2(
H
)one) was synthesized and reported its in vitro activity
on different enzymes. This study was a probe to investigate the toxicity
potential of that compound (SF3). Acute oral (425), subacute (407),
and teratogenicity (414) studies were planned according to their respective
guidelines given by organization of economic cooperation and development
(OECD). Acute oral, subacute, and teratogenicity studies were carried
out on 2000, 5–40, and 40 mg/kg doses. Blood samples were collected
for hematological and biochemical analyses. Vital organs were excised
for oxidative stress (superoxide dismutase, catalase, glutathione,
and malondialdehyde) and histopathological analysis.
LD
50
of SF3 was higher than 2000 mg/kg. In acute and subacute
studies, levels of alkaline phosphates and aspartate transaminase
were increased. Teratogenicity showed no resorptions, no skeletal
or soft tissue abnormalities, and no cleft pallet. Oxidative stress
biomarkers were close to the normal, and no increase in the malondialdehyde
level was seen. Histopathological studies revealed normal tissue architecture
of the selected organs, except kidney, in acute oral and subacute
toxicity studies at 40 mg/kg. The study concluded that SF3 is safer
if used as a drug.